Look at the amazing speaker list for Adhere2 next September!
This is going to be an excellent meeting, in beautiful Zadar, Croatia.
https://t.co/o6u0LywicO
6) High levels of GDI2 expression correlate with better patient survival
7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment
6) High levels of GDI2 expression correlate with better patient survival
7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment
A particularly intriguing observation: Invasion of trastuzumab resistant cells is αVβ6-independent. But resistant cells express very high levels αVβ6 on the cell surface. Opening up opportunities to potentially target them with an αVβ6-targeting warhead, or immuno-modulator
4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.
2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling.
3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.
We show that:
1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance.
Very excited to share our new paper on Talin binding to Amyloid Precursor Protein indicating a new way to think about Alzheimer's Disease.
It has the most provocative discussion section we have ever written :)
https://t.co/MfJtvQ91Db